Charles Faith L. purchased $34K of ABEO
Charles Faith L. purchased 15,000 shares of ABEONA THERAPEUTICS INC. (ABEO) at $2.29 on 2026-11-13.
ABEONA THERAPEUTICS INC.
Abeona is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. Its commercial product, ZEVASKYN, is an autologous gene-modified cellular sheet therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa. Abeona manufactures ZEVASKYN at its Cleveland, Ohio facility and commercializes it through qualified treatment centers; as of March 2026, it has activated 4 centers. Its development portfolio includes AAV-based gene therapy programs for ophthalmic diseases using AIM capsids, including programs for X-linked retinoschisis, Stargardt disease and autosomal dominant optic atrophy. Abeona makes money by commercializing ZEVASKYN and through licensing arrangements that provide for upfront, milestone and royalty payments. It has licensed AAV204 to Beacon Therapeutics for selected gene or disease targets and has out-licensed programs for Sanfilippo syndrome type A and Rett syndrome. Abeona is headquartered in Cleveland, Ohio.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Charles Faith L. purchased 15,000 shares of ABEONA THERAPEUTICS INC. (ABEO) at $2.29 on 2026-11-13.
HC Wainwright & Co. kept its Buy rating on Abeona Therapeutics but reduced its price target to $18 from $20, representing a 10% decrease. The new target suggests a 682.6% upside from the Nov 11 close of $2.30.
Abeona Therapeutics (NASDAQ:ABEO) plans a new Phase 3 trial for ABO-801, with $135M in cash and additional funding expected to cover development costs. ZEVASKYN, its FDA-approved gene therapy, has treated 15 patients, with 8 treatment centers active in the U.S. The company aims to expand these centers and is monitoring wound-healing observations.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ABEO (ABEONA THERAPEUTICS INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent ABEO coverage spans financial news, earnings and mergers & acquisitions.
In the last 30 days, ABEO insiders filed 1 SEC Form 4 transaction — 1 purchase ($34K) and no sales. The most active reporter was Charles Faith L. with 1 filing.
Small insider purchase with limited market impact.
HC Wainwright & Co. kept its Buy rating on Abeona Therapeutics but reduced its price target to $18 from $20, representing a 10% decrease. The new target suggests a 682.6% upside from the Nov 11 close of $2.30.
The Phase 3 announcement adds upside potential as investors price in future data readouts.
Potential upside as capacity increase and cash resources may improve margins; however short-term revenue may be constrained by shutdown.
Earnings beat is outweighed by heightened execution risk and cash‑burn concerns, likely keeping pressure on the share price.
AlphAI scores every news story that mentions ABEO with an AI model for sentiment and relevance, and aggregates insider trades from ABEONA THERAPEUTICS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Charles Faith L. purchased 15,000 shares of ABEONA THERAPEUTICS INC. (ABEO) at $2.29 on 2026-11-13.
HC Wainwright & Co. kept its Buy rating on Abeona Therapeutics but reduced its price target to $18 from $20, representing a 10% decrease. The new target suggests a 682.6% upside from the Nov 11 close of $2.30.
Abeona Therapeutics (NASDAQ:ABEO) plans a new Phase 3 trial for ABO-801, with $135M in cash and additional funding expected to cover development costs. ZEVASKYN, its FDA-approved gene therapy, has treated 15 patients, with 8 treatment centers active in the U.S. The company aims to expand these centers and is monitoring wound-healing observations.
Abeona Therapeutics reported an 18% revenue jump for ZivaSkin. CEO Vish Seshadri discussed plans to expand manufacturing capacity to 10 patients/month by mid-2027. CFO Joe Vizana expects 85%-90% gross margins at full capacity. ABO-801, an oral disintegrating tablet for EoE, is positioned as a convenient option. Abeona aims for a single Phase 3 trial for ABO-801, with estimated costs of $50M-$60M, covered by current cash and future sales.
Abeona Therapeutics (ABEO) reported Q3 2026 revenue growth of 18% to $13.5M, beating earnings expectations but missing revenue estimates. The company acquired ABO-801, a Phase 3-ready treatment, and expanded its treatment centers. Despite progress, shares fell 29.74% due to manufacturing challenges and cash burn concerns.
Abeona Therapeutics (ABEO) acquired APT-1011, a drug candidate for eosinophilic esophagitis, for $20 million in stock. The acquisition was announced on Monday.
ABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Abeona Therapeutics ® Reports Third Quarter 2026 Financial Results and ZEVASKYN ® Commercial Progress – Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 – – 15 ZEVASKYN treatments completed since launch, including six during Q3 – - QTC network ex
Abeona Therapeutics acquired APT-1011 assets from Ellodi Pharmaceuticals for 4.49M shares worth $20M, with up to $60M in potential milestones. Abeona also plans to raise $30M via private placement. Proceeds will support pipeline development and commercialization of ZEVASKYN.
ABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Abeona Therapeutics ® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement - Adds a once-daily, oral therapy candidate for eosinophilic esophagitis with FDA Orphan Drug and Fast Track Designations – – ABO-801 acqui
James Russell's trust reported a 6.1% stake in Abeona Therapeutics (ABEO) and plans to push for board and leadership changes. Russell met with directors, citing concerns about operations and governance. He may nominate candidates or oppose incumbents at the 2027 annual meeting. The trust spent $17.8 million on shares, including $3.7 million recently.